Retrospective Analysis of Antimicrobial Resistance Trends in Pseudomonas aeruginosa and Acinetobacter baumannii.

INTRODUCTION

The rise of antibiotic resistance poses a critical challenge to public health, particularly in managing infections caused by non-fermenting bacteria such as and This study aimed to determine the prevalent multi-drug resistance among non-fermentative Gram-negative bacteria isolated from hospitalized patients in a tertiary care center.

MATERIAL AND METHODS

A retrospective analysis was undertaken using one year of data from 2022 to 2023 to evaluate the antimicrobial resistance (AMR) profiles of and . The study assessed antibiotic resistance patterns, including piperacillin/tazobactam, carbapenems (imipenem, meropenem), ciprofloxacin, and colistin.

RESULTS

The analysis revealed resistance of to various antibiotics shows that piperacillin/tazobactam exhibited the highest resistance rate at 32% (181/565), while colistin exhibits the lowest at 5.6% (32/565). For , the resistance varies significantly among antibiotics, with piperacillin/tazobactam and ciprofloxacin showing the highest resistance rates at 56.8% (128/225) and 68% (153/225), respectively. In contrast, colistin is highly effective, with only 0.8% (2/225) resistance, and amikacin also demonstrates low resistance at 9.7% (22/225).

CONCLUSION

The growing trend of multi-drug and extensive drug resistance among non-fermenters such as  and necessitates urgent action. Establishing strict antibiotic policies, continuous monitoring of resistance patterns, and investment in antimicrobial research are imperative to combat the limited treatment options and manage these pathogens effectively.